|
Adma Biologics Inc (NASDAQ: ADMA) |
|
Adma Biologics Inc
ADMA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Adma Biologics Inc growth rates, revenue grew
by 40.67 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 312
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.76 %
Adma Biologics Inc's net income grew by 51.1 % in first quarter of 2025 year on year, above company average,
• More on ADMA's Growth
|
|
Adma Biologics Inc current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Adma Biologics Inc PEG ratio is at -0
Company is currently trading with Price to Cash flow multiple of 175.28 in trailing twelve-month period. |
Company |
19.54 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 8.49.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
• More on ADMA's Valuation
|
|
|
|
|
Adma Biologics Inc current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Adma Biologics Inc PEG ratio is at -0
Company is currently trading with Price to Cash flow multiple of 175.28 in trailing twelve-month period. |
Company |
19.54 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 8.49.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
Adma Biologics Inc Price to Book Ratio is at 11.62 lower than Industry Avg. of 1869. and higher than S&P 500 Avg. of 0.01
• More on ADMA's Valuation
|
|
ADMA's Profitability Comparisons
|
Adma Biologics Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 30.57 % from 40.43 % in IV. Quarter.
Adma Biologics Inc net profit margin of 23.58 % is currently ranking no. 12 in Biotechnology & Pharmaceuticals industry, ranking no. 45 in Healthcare sector and number 562 in S&P 500.
Profitability by Segment |
Total |
30.01 % |
|
|
Adma Biologics Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 30.57 % from 40.43 % in IV. Quarter.
Adma Biologics Inc net profit margin of 23.58 % is currently ranking no. 12 in Biotechnology & Pharmaceuticals industry, ranking no. 45 in Healthcare sector and number 562 in S&P 500.
• More on ADMA's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com